Breathe Well Live Well
|
Vectura Signs Up US Partner For VR315 Lung Drug
NASDAQ LN) said Wednesday it has signed a US licensing deal for its generic asthma medicine VR315 with an unnamed "leading international pharmaceutical company." VR315, a drug that industry observers say is a copycat version of GlaxoSmithKline PLC's (GSK. … Vectura signs US license agreement for VR315 product Vectura gets new US partner for copy of lung drug US deal for Vectura; takeover bid for AMAG |
View full post on asthma – Google News
|
Merck Withdraws Bid For EU Regulatory OK Of Asthma Medicine
NASDAQ (MRK) has withdrawn its application for European regulatory approval of an asthma treatment, citing outstanding questions by regulators. … |
View full post on asthma – Google News
|
US Court Upholds Injunction Protecting AstraZeneca Asthma Drug
NASDAQ LN) asthma drug Pulmicort Respules. The US Court of Appeals for the Federal Circuit upheld the injunction on a 2-1 vote. A federal trial judge in New Jersey … |
View full post on asthma – Google News
|
MediciNova (Nasdaq: MNOV) Targets Multi-Billion Dollar Acute Asthma and CNS …
BiotechStockTrader.com (blog) In particular, the company is targeting the multi-billion dollar acute asthma and central nervous system markets. With more than two million patients per … |
View full post on asthma – Google News